Pfizer (NYSE:PFE) Stock Rating Lowered by DZ Bank

Pfizer (NYSE:PFE) was downgraded by stock analysts at DZ Bank from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, MarketBeat reports.

Other equities research analysts also recently issued reports about the company. Argus set a $40.00 price target on Pfizer in a research note on Wednesday. JPMorgan Chase & Co. raised their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. UBS Group lifted their price objective on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. HSBC boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada upped their target price on Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research note on Wednesday. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $29.94.

Pfizer Stock Performance

NYSE PFE opened at $29.91 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 0.96. The firm has a market capitalization of $170.46 billion, a price-to-earnings ratio of 42.72, a P/E/G ratio of 2.04 and a beta of 0.31. The company’s fifty day moving average is $28.72 and its two-hundred day moving average is $26.88. Pfizer has a 52-week low of $23.62 and a 52-week high of $31.44.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The firm’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 earnings per share. Equities research analysts forecast that Pfizer will post 3.02 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC boosted its stake in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares in the last quarter. Keb Asset Management LLC bought a new stake in Pfizer in the second quarter valued at $26,000. Field & Main Bank bought a new stake in Pfizer in the second quarter valued at $27,000. Bullseye Investment Management LLC bought a new stake in Pfizer in the second quarter valued at $28,000. Finally, Timbuktu Capital Management LLC acquired a new position in Pfizer during the second quarter worth $29,000. Institutional investors own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat quarterly earnings and revenue expectations, and reports say it raised its 2026 outlook. Growth from newer and acquired products helped offset margin pressure, supporting confidence in the company’s turnaround. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Citigroup raised its price target on Pfizer, while a UBS analyst said the shares could rise. These calls add to favorable analyst sentiment following the earnings report. Pfizer Stock Gets Price Target Bump from Citigroup Pfizer Stock Price Expected to Rise, UBS Group Analyst Says
• Positive Sentiment: Pfizer is advancing a Phase 3 study of a monthly obesity drug. Progress in this competitive market could provide a future growth opportunity, although clinical results and commercial success remain uncertain. Pfizer Advances Monthly Obesity Drug Study
• Neutral Sentiment: Not all analysts are signaling strong upside: Goldman Sachs maintained a Hold rating, and recent target increases from Citi and UBS were accompanied by Neutral ratings. This suggests analysts see reasons for optimism but are not uniformly convinced of a major near-term rerating. Goldman Sachs Remains a Hold on Pfizer

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.